Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone in IgA Nephropathy
NCT06580288Phase 3Not yet recruiting
- Sponsor
- Zhejiang University
- Start
- Oct 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Finerenone with Placebo (2 arms). Primary endpoint: Change in urinary albumin/creatinine ratio at 12 months. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
finerenone
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06580288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06580288.